Prof. Axel Ullrich: The New--Realistic--Biotech Era
Executive Summary
Perhaps Europe's leading academic entrepreneur, professor Axel Ullrich, PhD, joined Genentech in its infancy, then, returning to Germany as a director of the Max-Planck Institute, swam against a generally anti-commercial tide within the German academic community by founding Sugen and several German start-ups, most recently, U3 Pharma. He describes the aftermath of Germany's BioRegio program and a new dose of realism in European biotech.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?